ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial
Wednesday, November 16, 2022
ZYUS Life Sciences Inc., a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the successful completion of database lock for its Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of Trichomylin® softgel capsules in healthy adult participants in Australia. The dataset has been transferred to the Company’s independent Clinical Research Organization for statistical analysis. Reaching a database lock also allows ZYUS to begin preparation for its Phase 2a clinical trial, expected to commence in 2023.
“This achievement marks an important milestone in ZYUS’ mission, to develop cannabinoid-based pharmaceutical drug products with meticulous scientific rigor,” said ZYUS CEO Brent Zettl. “We continue to pursue our clinical studies in osteoarthritic pain as previously announced. We believe the results of this Phase 1 clinical trial will bring us another step closer to providing patients with a regulatory-approved cannabinoid-based prescription drug for the alleviation of chronic pain.”
